Targeted Delivery of Arctigenin Using Sialic Acid Conjugate-Modified Liposomes for the Treatment of Breast Cancer

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2024 Jan 11

PMID 38202860

Authors

Shunfang Liu

Yaozhen He

Minding Feng

Yongtong Huang

Wenhao Wu

Jiu Wang

Affiliations

Soon will be listed here.

Abstract

Arctigenin (ATG) is a broad-spectrum antitumor drug with an excellent inhibitory effect on malignant tumors such as breast cancer, glioblastoma, liver cancer, and colon cancer. However, the clinical application of ATG is limited by its poor water solubility and quick hydrolysis in the liver, intestine, and plasma, which might hinder its application. Sialic acid (SA) recognizes selectin receptors overexpressed on the surface of tumor-associated macrophages. In this study, SA was conjugated with octadecylamine (ODA) to prepare SA-ODA, which was employed to prepare SA functionalized nanoliposomes (SA-Lip) to achieve breast cancer targeting. The formulations were finely optimized using the Box-Behnken design to achieve higher ATG loading. The size, ζ potential, entrapment efficiency, drug loading, and release behavior of ATG@SA-Lip were fully investigated in comparison with conventional ATG@Lip. The ATG@SA-Lip displayed more potent cytotoxicity and higher cellular internalization compared to ATG@Sol and ATG@Lip in both MCF7 and 4T1 cells. Notably, ATG@SA-Lip showed the lowest impact on the immune system. Our study demonstrates that SA-Lip has strong potential as a delivery system for the targeted delivery of ATG.

Citing Articles

Mechanistic and Therapeutic Implications of Protein and Lipid Sialylation in Human Diseases.

Zhong X, DAntona A, Rouse J Int J Mol Sci. 2024; 25(22).

PMID: 39596031 PMC: 11594235. DOI: 10.3390/ijms252211962.

References

Shi H, Zhao L, Guo X, Fang R, Zhang H, Dong G . Arctigenin Attenuates Breast Cancer Progression through Decreasing GM-CSF/TSLP/STAT3/β-Catenin Signaling. Int J Mol Sci. 2020; 21(17). PMC: 7503539. DOI: 10.3390/ijms21176357. View

Yan X, Gao X, Li X, Qiu Q, Li C, Yan N . Persistent immune response: Twice tumor exfoliation induced by sialic acid-modified vincristine sulfate liposomes. Int J Pharm. 2022; 631:122467. DOI: 10.1016/j.ijpharm.2022.122467. View

Grammer J, Kortum F, Wolburg H, Ludtke R, Schmidt K, Thiel H . Impregnation of collagen corneal shields with liposomes: uptake and release of hydrophilic and lipophilic marker substances. Curr Eye Res. 1996; 15(8):815-23. DOI: 10.3109/02713689609017622. View

He Y, Fan Q, Cai T, Huang W, Xie X, Wen Y . Molecular mechanisms of the action of Arctigenin in cancer. Biomed Pharmacother. 2018; 108:403-407. DOI: 10.1016/j.biopha.2018.08.158. View

Pearce O, Laubli H . Sialic acids in cancer biology and immunity. Glycobiology. 2015; 26(2):111-28. DOI: 10.1093/glycob/cwv097. View

Zhong Y, Lee K, Deng Y, Ma Y, Chen Y, Li X . Arctigenin attenuates diabetic kidney disease through the activation of PP2A in podocytes. Nat Commun. 2019; 10(1):4523. PMC: 6778111. DOI: 10.1038/s41467-019-12433-w. View

Steichen S, Caldorera-Moore M, Peppas N . A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur J Pharm Sci. 2012; 48(3):416-27. PMC: 3619023. DOI: 10.1016/j.ejps.2012.12.006. View

Gu Y, Scheuer C, Feng D, Menger M, Laschke M . Inhibition of angiogenesis: a novel antitumor mechanism of the herbal compound arctigenin. Anticancer Drugs. 2013; 24(8):781-91. DOI: 10.1097/CAD.0b013e328362fb84. View

Gao Q, Yang M, Zuo Z . Overview of the anti-inflammatory effects, pharmacokinetic properties and clinical efficacies of arctigenin and arctiin from Arctium lappa L. Acta Pharmacol Sin. 2018; 39(5):787-801. PMC: 5943914. DOI: 10.1038/aps.2018.32. View

10.

Kim Y, Min K, Wang Z, Kim J, Jacobson O, Huang P . Development of Sialic Acid-coated Nanoparticles for Targeting Cancer and Efficient Evasion of the Immune System. Theranostics. 2017; 7(4):962-973. PMC: 5381258. DOI: 10.7150/thno.19061. View

11.

Fornaguera C, Solans C . Methods for the In Vitro Characterization of Nanomedicines-Biological Component Interaction. J Pers Med. 2017; 7(1). PMC: 5374392. DOI: 10.3390/jpm7010002. View

12.

Jiang Y, Liu J, Hong W, Fei X, Liu R . Arctigenin Inhibits Glioblastoma Proliferation through the AKT/mTOR Pathway and Induces Autophagy. Biomed Res Int. 2020; 2020:3542613. PMC: 7512051. DOI: 10.1155/2020/3542613. View

13.

Stanczak M, Siddiqui S, Trefny M, Thommen D, Boligan K, von Gunten S . Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells. J Clin Invest. 2018; 128(11):4912-4923. PMC: 6205408. DOI: 10.1172/JCI120612. View

14.

Guimaraes D, Cavaco-Paulo A, Nogueira E . Design of liposomes as drug delivery system for therapeutic applications. Int J Pharm. 2021; 601:120571. DOI: 10.1016/j.ijpharm.2021.120571. View

15.

Tang X, Yu C, Lei Y, Wang Z, Wang C, Wang J . A novel chitosan-urea encapsulated material for persulfate slow-release to degrade organic pollutants. J Hazard Mater. 2021; 426:128083. DOI: 10.1016/j.jhazmat.2021.128083. View

16.

Li C, Qiu Q, Liu M, Liu X, Ling Hu , Luo X . Sialic acid-conjugate modified liposomes targeting neutrophils for improved tumour therapy. Biomater Sci. 2020; 8(8):2189-2201. DOI: 10.1039/c9bm01732a. View

17.

Zheng J, Zheng S, Zhang Y, Yu B, Zheng W, Yang F . Sialic acid surface decoration enhances cellular uptake and apoptosis-inducing activity of selenium nanoparticles. Colloids Surf B Biointerfaces. 2010; 83(1):183-7. DOI: 10.1016/j.colsurfb.2010.11.023. View

18.

Naoe A, Tsuchiya T, Kondo Y, Uga N, Watanabe S, Yasui T . Arctigenin induces apoptosis in human hepatoblastoma cells. Pediatr Surg Int. 2019; 35(6):723-728. DOI: 10.1007/s00383-019-04473-6. View

19.

Barkal A, Brewer R, Markovic M, Kowarsky M, Barkal S, Zaro B . CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. 2019; 572(7769):392-396. PMC: 6697206. DOI: 10.1038/s41586-019-1456-0. View

20.

Zhu L, Shen X, Yuan P, Shao T, Wang G, Liu X . Arctigenin inhibits proliferation of ER-positive breast cancer cells through cell cycle arrest mediated by GSK3-dependent cyclin D1 degradation. Life Sci. 2020; 256:117983. DOI: 10.1016/j.lfs.2020.117983. View